ResearcherInstitut Químic de SarriàActive in the last 2 years
Carlos E. Semino
Matched on ORCID iD 0000-0002-6712-8418; OpenAlex author ID A5060327052.
Their work
- Papers
- 4 (first author 0, last author 3)
- Trials
- 0
- Grants
- 0
- Labs led
- 1
- Collaborators
- 3
2021: 2 papers · 2022: 1 paper · 2023: none · 2024: none · 2025: none · 2026: 1 paper
Papers 4
- uPAR-targeted stealth small-sized mesoporous silica nanoparticles for pancreatic cancer therapy. Co-author DOI 10.1007/s13346-026-02139-0↗
- Increased Stiffness Downregulates Focal Adhesion Kinase Expression in Pancreatic Cancer Cells Cultured in 3D Self-Assembling Peptide Scaffolds. Last author DOI 10.3390/biomedicines10081835↗
- Syndecans and Pancreatic Ductal Adenocarcinoma. Last author DOI 10.3390/biom11030349↗
- Erlotinib Promotes Ligand-Induced EGFR Degradation in 3D but Not 2D Cultures of Pancreatic Ductal Adenocarcinoma Cells. Last author DOI 10.3390/cancers13184504↗
Closest collaborators
The 3 strongest of 3 ranked by shared papers, trials and grants, with recent and small-team work weighing most.
- Nausika Betriu · 3 shared papers, 2021–2022
- Paper Increased Stiffness Downregulates Focal Adhesion Kinase Expression in Pancreatic Cancer Cells Cultured in 3D Self-Assem… DOI 10.3390/biomedicines10081835↗
- Paper Erlotinib Promotes Ligand-Induced EGFR Degradation in 3D but Not 2D Cultures of Pancreatic Ductal Adenocarcinoma Cells. DOI 10.3390/cancers13184504↗
- Paper Syndecans and Pancreatic Ductal Adenocarcinoma. DOI 10.3390/biom11030349↗
- Iris Pontón · 1 shared paper, 2026
- David Sánchez-García · 1 shared paper, 2026
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (the fewest links first, then the links with the most shared work). Built from public records only; no contact details are kept.